Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Randomized, Multiple-dosing Parallel Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-355 With D797 and D324 in Healthy Subjects

NCT03802162 is registered in ClinicalTrials.gov with Chong Kun Dang Pharmaceutical as lead sponsor.

NCT NCT03802162
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03802162 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Randomized, Multiple-dosing Parallel Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-355 With D797 and D324 in Healthy Subjects
Lead sponsor
Chong Kun Dang Pharmaceutical
Phase
Phase 1
Overall status
Completed
Start date
February 15, 2019
Completion date
August 31, 2019
Enrollment
60 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease (ad)